Works by Jagannath, Sundar

Results: 185
    1
    2
    3

    Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry.

    Published in:
    Cancers, 2021, v. 13, n. 23, p. 5996, doi. 10.3390/cancers13235996
    By:
    • Merz, Maximilian;
    • Goldschmidt, Hartmut;
    • Hari, Parameswaran;
    • Agha, Mounzer;
    • Diels, Joris;
    • Ghilotti, Francesca;
    • Perualila, Nolen J.;
    • Cabrieto, Jedelyn;
    • Haefliger, Benjamin;
    • Sliwka, Henrik;
    • Schecter, Jordan M.;
    • Jackson, Carolyn C.;
    • Olyslager, Yunsi;
    • Akram, Muhammad;
    • Nesheiwat, Tonia;
    • Kellermann, Lenka;
    • Jagannath, Sundar
    Publication type:
    Article
    4
    5
    6

    Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.

    Published in:
    Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01330-3
    By:
    • Elnaggar, Muhammad;
    • Agte, Sarita;
    • Restrepo, Paula;
    • Ram, Meghana;
    • Melnekoff, David;
    • Adamopoulos, Christos;
    • Stevens, Mark M.;
    • Kappes, Katerina;
    • Leshchenko, Violetta;
    • Verina, Daniel;
    • Jagannath, Sundar;
    • Poulikakos, Poulikos I.;
    • Parekh, Samir;
    • Laganà, Alessandro
    Publication type:
    Article
    7

    Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 6, p. 1, doi. 10.1038/s41408-022-00695-5
    By:
    • Kumar, Shaji;
    • Baizer, Lawrence;
    • Callander, Natalie S.;
    • Giralt, Sergio A.;
    • Hillengass, Jens;
    • Freidlin, Boris;
    • Hoering, Antje;
    • Richardson, Paul G.;
    • Schwartz, Elena I.;
    • Reiman, Anthony;
    • Lentzsch, Suzanne;
    • McCarthy, Philip L.;
    • Jagannath, Sundar;
    • Yee, Andrew J.;
    • Little, Richard F.;
    • Raje, Noopur S.
    Publication type:
    Article
    8
    9
    10

    Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.

    Published in:
    Blood Cancer Journal, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41408-020-00397-w
    By:
    • Premkumar, Vikram J.;
    • Lentzsch, Suzanne;
    • Pan, Samuel;
    • Bhutani, Divaya;
    • Richter, Joshua;
    • Jagannath, Sundar;
    • Liedtke, Michaela;
    • Jaccard, Arnaud;
    • Wechalekar, Ashutosh D.;
    • Comenzo, Raymond;
    • Sanchorawala, Vaishali;
    • Royer, Bruno;
    • Rosenzweig, Michael;
    • Valent, Jason;
    • Schönland, Stefan;
    • Fonseca, Rafael;
    • Wong, Sandy;
    • Kapoor, Prashant
    Publication type:
    Article
    11

    Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.

    Published in:
    Leukemia & Lymphoma, 2016, v. 57, n. 12, p. 2833, doi. 10.1080/10428194.2016.1177181
    By:
    • Siegel, David S.;
    • Weisel, Katja C.;
    • Dimopoulos, Meletios A.;
    • Baz, Rachid;
    • Richardson, Paul;
    • Delforge, Michel;
    • Song, Kevin W.;
    • San Miguel, Jesus F.;
    • Moreau, Philippe;
    • Goldschmidt, Hartmut;
    • Cavo, Michele;
    • Jagannath, Sundar;
    • Yu, Xin;
    • Hong, Kevin;
    • Sternas, Lars;
    • Zaki, Mohamed;
    • Palumbo, Antonio
    Publication type:
    Article
    12
    13
    14

    Trial designs and endpoints for immune therapies in multiple myeloma.

    Published in:
    American Journal of Hematology, 2023, v. 98, p. S35, doi. 10.1002/ajh.26753
    By:
    • Lancman, Guido;
    • Moshier, Erin;
    • Cho, Hearn Jay;
    • Parekh, Samir;
    • Richard, Shambavi;
    • Richter, Joshua;
    • Rodriguez, Cesar;
    • Rossi, Adriana;
    • Sanchez, Larysa;
    • Jagannath, Sundar;
    • Chari, Ajai
    Publication type:
    Article
    15

    Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.

    Published in:
    American Journal of Hematology, 2021, v. 96, n. 1, p. E5, doi. 10.1002/ajh.26010
    By:
    • Cornell, Robert;
    • Hari, Parameswaran;
    • Tang, Shijie;
    • Biran, Noa;
    • Callander, Natalie;
    • Chari, Ajai;
    • Chhabra, Saurabh;
    • Fiala, Mark A.;
    • Gahvari, Zhubin;
    • Gandhi, Ujjawal;
    • Godby, Kelly;
    • Gupta, Ridhi;
    • Jagannath, Sundar;
    • Jagosky, Megan;
    • Kang, Yubin;
    • Kansagra, Ankit;
    • Kauffman, Michael;
    • Kodali, Saranya;
    • Kumar, Shaji K.;
    • Lakshman, Arjun
    Publication type:
    Article
    16

    Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m<sup>2</sup> in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m<sup>2</sup>.

    Published in:
    American Journal of Hematology, 2020, v. 95, n. 2, p. E51, doi. 10.1002/ajh.25695
    By:
    • Barley, Kevin;
    • Sanchez, Larysa;
    • Cho, Hearn J.;
    • Parekh, Samir;
    • Madduri, Deepu;
    • Richter, Joshua;
    • Isola, Luis;
    • Goldstein, Talia;
    • Dhadwal, Amishi;
    • Zarychta, Katarzyna;
    • Sanchez, Gillian Morgan;
    • Catamero, Donna;
    • Verina, Daniel;
    • Florendo, Erika;
    • Yum, Moon‐hee;
    • La, Lisa;
    • Gullie, Jude;
    • Chan, Elaine;
    • Jagannath, Sundar;
    • Chari, Ajai
    Publication type:
    Article
    17
    18

    Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.

    Published in:
    Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01177-6
    By:
    • Ailawadhi, Sikander;
    • Lee, Hans C.;
    • Omel, James;
    • Toomey, Kathleen;
    • Hardin, James W.;
    • Gasparetto, Cristina J.;
    • Jagannath, Sundar;
    • Rifkin, Robert M.;
    • Durie, Brian G. M.;
    • Narang, Mohit;
    • Terebelo, Howard R.;
    • Joshi, Prashant;
    • Jou, Ying-Ming;
    • Mouro, Jorge;
    • Yu, Edward;
    • Abonour, Rafat
    Publication type:
    Article
    19
    20
    21

    Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the Connect® MM Registry.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2025, v. 25, n. 12, p. 58, doi. 10.1016/j.clml.2024.11.001
    By:
    • Terebelo, Howard R.;
    • Omel, James;
    • Wagner, Lynne I.;
    • Hardin, James W.;
    • Rifkin, Robert M.;
    • Ailawadhi, Sikander;
    • Durie, Brian G. M.;
    • Narang, Mohit;
    • Toomey, Kathleen;
    • Gasparetto, Cristina J.;
    • Joshi, Prashant;
    • Yu, Edward;
    • Flick, E. Dawn;
    • Ying-Ming Jou;
    • Lee, Hans C.;
    • Abonour, Rafat;
    • Jagannath, Sundar
    Publication type:
    Article
    22

    The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the Connect® MM Registry.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 10, p. e336, doi. 10.1016/j.clml.2024.05.021
    By:
    • Abonour, Rafat;
    • Lee, Hans C.;
    • Rifkin, Robert;
    • Ailawadhi, Sikander;
    • Omel, James;
    • Hardin, James W.;
    • Narang, Mohit;
    • Toomey, Kathleen;
    • Gasparetto, Cristina;
    • Wagner, Lynne I.;
    • Terebelo, Howard;
    • Mouro, Jorge;
    • Dhanasiri, Sujith;
    • Liu, Liang;
    • Yu, Edward;
    • Jagannath, Sundar
    Publication type:
    Article
    23
    24
    25
    26
    27

    Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 2, p. 112, doi. 10.1016/j.clml.2022.11.008
    By:
    • Lee, Hans C.;
    • Ramasamy, Karthik;
    • Weisel, Katja;
    • Abonour, Rafat;
    • Hardin, James W.;
    • Rifkin, Robert M.;
    • Ailawadhi, Sikander;
    • Terebelo, Howard R.;
    • Durie, Brian G.M.;
    • Tang, Derek;
    • Joshi, Prashant;
    • Liu, Liang;
    • Jou, Ying-Ming;
    • Che, Min;
    • Hernandez, Gabriela;
    • Narang, Mohit;
    • Toomey, Kathleen;
    • Gasparetto, Cristina;
    • Wagner, Lynne I.;
    • Jagannath, Sundar
    Publication type:
    Article
    28
    29
    30

    Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 9, p. 690, doi. 10.1016/j.clml.2022.04.025
    By:
    • Weisel, Katja;
    • Krishnan, Amrita;
    • Schecter, Jordan M.;
    • Vogel, Martin;
    • Jackson, Carolyn C.;
    • Deraedt, William;
    • Yeh, Tzu-min;
    • Banerjee, Arnob;
    • Yalniz, Fevzi;
    • Nesheiwat, Tonia;
    • Sanden, Suzy Van;
    • Diels, Joris;
    • Valluri, Satish;
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Jagannath, Sundar;
    • Martin, Tom
    Publication type:
    Article
    31

    A New Reality for Multiple Myeloma Renal Failure: US Data Report on Kidney Transplant Outcomes.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 5, p. e314, doi. 10.1016/j.clml.2021.11.002
    By:
    • Costa, Luciano J.;
    • Lin, Yi;
    • Cornell, R. Frank;
    • Martin, Thomas;
    • Chhabra, Saurabh;
    • Usmani, Saad Z.;
    • Jagannath, Sundar;
    • Callander, Natalie S.;
    • Berdeja, Jesus G.;
    • Kang, Yubin;
    • Vij, Ravi;
    • Godby, Kelly N.;
    • Malek, Ehsan;
    • Neppalli, Amarendra;
    • Liedtke, Michaela;
    • Fiala, Mark;
    • Tian, Hong;
    • Valluri, Satish;
    • Marino, Jennifer;
    • Jackson, Carolyn C.
    Publication type:
    Article
    32
    33

    Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 3, p. 149, doi. 10.1016/j.clml.2021.08.007
    By:
    • Gasparetto, Cristina;
    • Jagannath, Sundar;
    • Rifkin, Robert M.;
    • Durie, Brian G.M.;
    • Narang, Mohit;
    • Terebelo, Howard R.;
    • Toomey, Kathleen;
    • Hardin, James W.;
    • Wagner, Lynne;
    • Ailawadhi, Sikander;
    • Omel, James L.;
    • Srinivasan, Shankar;
    • Dhalla, Mazaher;
    • Catamero, Donna;
    • Kitali, Amani;
    • Agarwal, Amit;
    • Abonour, Rafat
    Publication type:
    Article
    34
    35
    36

    NP-114: Lesson Learned: Management of patients with Multiple Myeloma (MM) and their response to two doses of COVID-19 RNA vaccine.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S171, doi. 10.1016/S2152-2650(21)02367-3
    By:
    • Verina, Daniel;
    • Van Oekelen, Oliver;
    • Gleason, Charles;
    • Agte, Sarita;
    • Srivastava, Komal;
    • Beach, Katherine;
    • Aleman, Adolfo;
    • Mouhieddine, Tarek;
    • Chari, Ajai;
    • Cordon-Cardo, Carlos;
    • Krammer, Florian;
    • Jagannath, Sundar;
    • Simon, Viviana;
    • Wajnberg, Ania;
    • Parekh, Samir
    Publication type:
    Article
    37

    P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02330-2
    By:
    • Lonial, Sagar;
    • Berdeja, Jesus G.;
    • Dimopoulos, Meletios-Athanasios;
    • Jagannath, Sundar;
    • Knop, Stefan;
    • Hang Quach;
    • Rodríguez-Otero, Paula;
    • Richardson, Paul G.;
    • Sorrell, April;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • Tuong Vi Nguyen;
    • Hong, Kevin;
    • Peluso, Teresa;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    38

    P-136: Health-related quality of life (HRQL) among real-world Ide-Cel–eligible patients (pts) with relapsed/refractory Multiple Myeloma (RRMM): results from the Connect® MM registry.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S109, doi. 10.1016/S2152-2650(21)02263-1
    By:
    • Wagner, Lynne;
    • Abonour, Rafat;
    • Ailawadhi, Sikander;
    • Durie, Brian G.M.;
    • Gasparetto, Cristina J.;
    • Hardin, James W.;
    • Lee, Hans;
    • Narang, Mohit;
    • Rifkin, Robert;
    • Terebelo, Howard;
    • Toomey, Kathleen;
    • Joshi, Prashant;
    • Agarwal, Amit;
    • Braverman, Julia;
    • Dhanda, Devender S.;
    • Mia He;
    • Jagannath, Sundar
    Publication type:
    Article
    39
    40
    41
    42

    P-063: Pathogenic germline variants in hereditary cancer genes in patients with Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S73, doi. 10.1016/S2152-2650(21)02197-2
    By:
    • Thibaud, Santiago;
    • Etra, Aaron;
    • Subaran, Ryan;
    • Soens, Zachry;
    • Newman, Scott;
    • Rong Chen;
    • Chari, Ajai;
    • Cho, Hearn Jay;
    • Jagannath, Sundar;
    • Madduri, Deepu;
    • Melnekoff, David;
    • Richard, Shambavi;
    • Richter, Joshua;
    • Sanchez, Larysa;
    • Kuan-Lin Huang;
    • Lagana, Alessandro;
    • Parekh, Samir;
    • Onel, Kenan
    Publication type:
    Article
    43
    44

    OAB-048: Suboptimal humoral immune response to SARS-CoV-2 mRNA vaccination in myeloma patients is associated with anti-CD38 mAb and BCMA-targeted treatment.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S30, doi. 10.1016/S2152-2650(21)02122-4
    By:
    • Oekelen, Oliver Van;
    • Agte, Sarita;
    • Gleason, Charles;
    • Srivastava, Komal;
    • Beach, Katherine;
    • Aleman, Adolfo;
    • Upadhyaya, Bhaskar;
    • Kappes, Katerina;
    • Mouhieddine, Tarek;
    • Bo Wang;
    • Chari, Ajai;
    • Cordon-Cardo, Carlos;
    • Krammer, Florian;
    • Jagannath, Sundar;
    • Simon, Viviana;
    • Wajnberg, Ania;
    • Parekh, Samir
    Publication type:
    Article
    45

    OAB-024: Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S15, doi. 10.1016/S2152-2650(21)02098-X
    By:
    • Jagannath, Sundar;
    • Berdeja, Jesus G.;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam;
    • Madduri, Deepu;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C.;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Pacaud, Lida;
    • Akram, Muhammad;
    • Lin, Yi;
    • Martin, Thomas;
    • Usmani, Saad Z.
    Publication type:
    Article
    46

    OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S17, doi. 10.1016/S2152-2650(21)02101-7
    By:
    • Anderson, Jr., Larry D.;
    • Nina Shah;
    • Jagannath, Sundar;
    • Berdeja, Jesus G.;
    • Lonial, Sagar;
    • Raje, Noopur;
    • Siegel, David S.;
    • Yi Lin;
    • Moreau, Philippe;
    • Yakoub-Agha, Ibrahim;
    • Delforge, Michel;
    • Einsele, Hermann;
    • Goldschmidt, Hartmut;
    • Weisel, Katja;
    • Cavo, Michele;
    • Reece, Donna E.;
    • Rambaldi, Alessandro;
    • Truppel-Hartmann, Anna;
    • Patel, Payal;
    • Liping Huang
    Publication type:
    Article
    47

    OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
    By:
    • Lonial, Sagar;
    • Richardson, Paul G.;
    • Popat, Rakesh;
    • Stadtmauer, Edward A.;
    • Larsen, Jeremy T.;
    • Oriol, A.;
    • Knop, Stefan;
    • Jagannath, Sundar;
    • Cook, Gordon;
    • Badros, Ashraf Z.;
    • Rodríguez-Otero, Paula;
    • Siegel, David S.;
    • Tuong Vi Nguyen;
    • Micco, Antonia Di;
    • Amin, Alpesh;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    48

    MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S422, doi. 10.1016/S2152-2650(21)01946-7
    By:
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Madduri, Deepu;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam D.;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Lin, Yi;
    • Martin, Thomas;
    • Jagannath, Sundar
    Publication type:
    Article
    49

    Poster: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S249, doi. 10.1016/S2152-2650(21)01569-X
    By:
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Madduri, Deepu;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam D.;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Lin, Yi;
    • Martin, Thomas;
    • Jagannath, Sundar
    Publication type:
    Article
    50

    Oral Abstract: MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S202, doi. 10.1016/S2152-2650(21)01275-1
    By:
    • Usmani, Saad Z.;
    • Berdeja, Jesus G.;
    • Madduri, Deepu;
    • Jakubowiak, Andrzej;
    • Agha, Mounzer;
    • Cohen, Adam D.;
    • Hari, Parameswaran;
    • Yeh, Tzu-Min;
    • Olyslager, Yunsi;
    • Banerjee, Arnob;
    • Jackson, Carolyn C;
    • Allred, Alicia;
    • Zudaire, Enrique;
    • Deraedt, William;
    • Wu, Xiaoling;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Yi Lin;
    • Martin, Thomas;
    • Jagannath, Sundar
    Publication type:
    Article